Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Sun Yat-sen University
Shengjing Hospital
Africa Middle East Cancer Intergroup
Guangdong Provincial People's Hospital
Blokhin's Russian Cancer Research Center
First Hospital of China Medical University
Gruppo Italiano Mammella (GIM)
Amsterdam UMC, location VUmc
Fuzhou General Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Xijing Hospital
Peking Union Medical College Hospital
Samsung Medical Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Midwestern Regional Medical Center
Sun Yat-sen University
Irmandade da Santa Casa de Misericordia de Sao Paulo
National University Hospital, Singapore
Consorzio Oncotech
Organisation for Oncology and Translational Research
Tianjin Medical University
Fudan University